Mastocytos - En sjukdom med många ansikten: Utredning och behandling bör ske i samråd med Karolinska Universitetssjukhuset

Lakartidningen

Volumn 105, Issue 46, 2008, Pages 3341-3347

  Hägglund, Hans ^a   Gülen, Theo ^a   Sääf, Maria ^a   Sander, Birgitta ^a,b   Nilsson, Gunnar ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Karolinska Institutet ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLASSIFICATION; CLINICAL COMPETENCE; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOLOGY; INTERNATIONAL COOPERATION; MAST CELL; MASTOCYTOSIS; PATHOLOGY; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA;

CLINICAL COMPETENCE; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTERNATIONAL COOPERATION; MAST CELLS; MASTOCYTOSIS; MASTOCYTOSIS, CUTANEOUS; MASTOCYTOSIS, SYSTEMIC;

EID: 56749180771     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus state ments on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435-53.
2. Nilsson G, Costa JJ, Metcalfe DD. Mast cells and basophils. In: Gallin JI, Snyderman R, editors. Inflammation: basic principles and clinical correlates. Philadelphia, PA: Lippincott-Raven publications; 1999. p. 97-117.
3. Fischer M, Harvima IT, Carvalho RF, Möller C, Naukkarinen A, Enblad G, et al. Mast cell CD30 ligand is up-regulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006;116:2748-56.
4. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as »tunable« effector and immunoregulatory cells: Recent advances. Annu Rev Immunol. 2005;23:749-86.
5. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A. 1995;92:10560-4.
6. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A. 1999;96:1609-14.
7. Valent P, Akin C, Sperr WR, Mayerhoffer M, Födinger M, Fritsche-Polanz R, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma. 2005;46:35-48.
8. Roupe G. Mastocytos - två sjukdomar med olika patofysiologi. Läkartidningen. 2002;99:2400-4.
9. Patnaik MM, Rindos M, Kouides PA, Tefferi A, Pardanani A. Systemic mastocytosis: a concise clinical and laboratory review. Arch Pathol Lab Med. 2007;131:784-91.
10. Chiappetta N, Gruber B. The role of mast cells in osteoporosis. Semin. Arthritis Rheum. 2006;36:32-6.
11. Kluin-Nelemans HC, Jansen JH, Breukelman H, Wolthers BG, Kluin PM, Kroon HM, et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N Engl J Med. 1992;326:619-23.
12. Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med. 2001;344:307-9.
13. Akin C, Brockow K, D'Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31:686-92.
14. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222-5.
15. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Bohm A, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. 2006;107:752-9.
16. Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108:286-91.
17. Gabillot-Carré M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP, et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood. 2006;108:1065-72.
18. Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood. 2007;109:3031-41.
19. Möller C, Alfredsson J, Engström M, Wootz H, Xiang Z, Lennartsson J, et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a mediated transcriptional induction and MEK regulated phosphorylation of the pro-apoptotic protein Bim. Blood. 2005;106:1330-6.